<DOC>
	<DOCNO>NCT02722538</DOCNO>
	<brief_summary>The purpose study determine TAR-200 , investigational drug-delivery system , safe tolerable patient muscle-invasive bladder cancer ( MIBC ) diagnosis radical cystectomy ( RC ) .</brief_summary>
	<brief_title>Safety Tolerability GemRIS 225 mg Subjects With Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histological proof muscleinvasive transitional cell carcinoma bladder ( stage IIIII ) . Subjects evidence metastatic nodal disease obuturator presacral lymph node may include ( N1 M0 ) . Subjects degree fixation pelvic sidewall eligible . In Arm 1 , subject must residual visible tumor follow TURBT . In Arm 2 , subject must fully resect ( i.e. , visible tumor little tumor possible ) restaging TURBT 26 week prior Study Day 0 . Adequate bone marrow , liver , renal function , assess follow requirement conduct within 21 day prior dose : 1 . Hemoglobin ≥ 9.0 g/dL 2 . Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 3 . Platelet count ≥ 100,000/mm3 4 . Total bilirubin ≤ 1.5xULN ( upper limit normal ) 5 . Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤ 2.5xULN 6 . Glomerular Filtration Rate ( GFR ) ≥ 30 % ( ≥ 30 ml/min/1.73 m2 ) Subjects must willing undergo cystoscopy study investigational product removal . Eligible willing undergo RC per attend urologist . Subjects must deem ineligible cisplatinbased combination chemotherapy attend medical oncologist . Subjects medically eligible neoadjuvant cisplatinbased combination chemotherapy refuse therapeutic option understand risk benefit . Prior radiation therapy allow provide radiation therapy administer urinary bladder . Written inform consent Health Insurance Portability Accountability Act 1966 ( HIPAA ) authorization release personal health information . Age &gt; 18 year time consent . Active malignancy within 12 month exception negligible risk metastasis death treat expect curative outcome . Prior systemic chemotherapy transitional cell carcinoma bladder . Any prior systemic chemotherapy nonurothelial carcinoma must complete &gt; 5 year prior initiation study . Previous exposure gemcitabine instillation . Currently receive intravesical chemotherapy . Concurrent clinically significant infection determine treat investigator . Presence bladder urethral anatomic feature opinion investigator may prevent safe placement , indwell use removal TAR200 . Documented history vesicoureteral reflux presence indwell ureteral stent nephrostomy tube time screen . Pelvic radiotherapy administer within less 6 month prior enrollment . Subjects receive radiotherapy ≥ 6 month prior enrollment must demonstrate cystoscopic evidence symptom radiation cystitis . Bladder PostVoid Residual Volume ( PVR ) &gt; 250mL . Active , uncontrolled urogenital bacterial , viral fungal infection , include urinary tract infection opinion investigator , contraindicate participation . Skin/nail fungal infection exclusionary . Subjects active shingle ( varicella zoster infection ) exclude study . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , gynecological , endocrine , immunological , dermatological , neurological psychiatric disease disorder , opinion investigator , contraindicate participation . History diagnosis neurogenic bladder . Concomitant immunosuppressive medication , methotrexate TNF inhibitor , within 2 week Study Day 0 , exclusive steroid dos ≤ 5 mg daily . Difficulty provide blood sample . Unwilling unable provide inform consent comply requirement protocol , include presence condition ( physical , mental social ) likely affect subject 's return schedule visit followup . Other unspecified reason , opinion investigator TARIS , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>